Duagen Articles
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
Gilead and GlaxoSmithKline to commercialize Viread for chronic hepatitis B in key Asian countries; update on Avodart
26 November 2009
GlaxoSmithKline beats forecasts with 3rd quarter2009 profits leaping 34%, despite generic competition
28 October 2009
New guidelines to help boost use of 5-ARIs
9 March 2009
FDA says TV ad for GSK
9 March 2009
US FTC closes, freezes assets of vast drug spam e-mail network
27 October 2008
FDA approval for GSK's Avodart
30 June 2008
PIP recommendations from EMEA's PDCO
26 May 2008
GSK's combo drug "to be BPH gold standard by 2011"
3 March 2008
Barr challenges GSK's Avodart patent
3 March 2008
Strong 24-month performance for GSK's Advodart
10 September 2007
GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure
30 April 2007
Long-term benefit with GSK's Avodart in BPH
5 April 2004
GSK begins Avodart combination trial
22 December 2003
Four-year Avodart data reinforce role in BPH
5 May 2003
GSK launches Avodart in UK
3 March 2003
2002's crop of new product launches backs up R&D fears
10 February 2003
GSK's dutasteride for BPH cleared in USA
7 January 2002
GSK's dutasteride for BPH cleared in USA
28 December 2001
Showing 1-27 of 27 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
